Which comes first for PTSD, cannabis or antidepressants?
Antidepressants come first. Sertraline and paroxetine are the only drugs with FDA approval for PTSD, and the VA/DoD clinical practice guideline lists them as first-line medication alongside trauma-focused therapy. No cannabis product holds FDA approval for PTSD, so cannabis stays a secondary option for people who cannot tolerate or do not respond to standard treatment.
How do they compare on the factors that decide?
- Evidence: strong and replicated for SSRIs, limited and mixed for cannabis.
- Approval: FDA-approved PTSD indication versus no approved cannabis indication.
- Access: appointment plus pharmacy pickup versus state medical program or retail dispensary.
- Dosing: fixed milligrams with a titration schedule versus variable THC and CBD potency.
- Cost: generic SSRIs run a few dollars a month; cannabis is often out of pocket.
Why antidepressants take the top pick
Both approved drugs reduce re-experiencing, avoidance, and hyperarousal in controlled trials. Response usually shows up in two to four weeks, and full benefit can take eight to twelve weeks. That wait is the main reason people look at cannabis instead.
Pick: sertraline
Sertraline is the usual starting point because it has the widest safety data and a gentle titration, often 25 to 50 mg at first and 50 to 200 mg as a target. It has fewer withdrawal problems than paroxetine. Most people tolerate it with mild nausea or sleep changes that fade.
Medical Marijuana for PTSD: 2024 Research Updates
Runner-up: paroxetine
Paroxetine works at 20 to 60 mg and is equally approved for PTSD. It carries more anticholinergic effects and harder discontinuation, so it suits people who need a faster sedating effect or who have not done well on sertraline.
Off-label option: venlafaxine
Venlafaxine is not FDA-approved for PTSD but appears in guidelines as a reasonable second-line switch. It can help when depression and anxiety overlap with trauma symptoms.
Where cannabis wins on convenience
Cannabis beats antidepressants on speed of access in most legal states. A medical card or a retail purchase can put a product in hand the same day, while an SSRI requires an appointment, a prescription, and weeks before symptoms shift. That gap is why convenience has become the deciding factor for many buyers.
Convenience is not the same as effectiveness. Longitudinal research links frequent cannabis use to more severe PTSD symptoms over time, and withdrawal can mimic the anxiety and insomnia people were trying to treat.
What about CBD?
CBD carries less intoxication risk than THC, and early trials are small and short. The evidence is not strong enough to place CBD ahead of an approved SSRI.
Which option is safer?
SSRIs carry a boxed warning for suicidal thoughts in people under 25 and can cause sexual side effects and nausea. Cannabis carries risks of dependence, cognitive effects, and cannabis use disorder, and heavy use may worsen outcomes. Combining cannabis with an SSRI can change how the liver metabolizes the antidepressant, so a clinician should know about both.
What should you ask before choosing?
- Has a clinician confirmed the PTSD diagnosis and screened for depression, bipolar disorder, and substance use?
- Is trauma-focused therapy available, since it outperforms medication alone?
- If an SSRI fails, is the next step a switch, an add-on, or supervised cannabis?
- Is cannabis legal in your state, and who will track dose and potency?
Bottom line
Pick an FDA-approved antidepressant first, pair it with trauma-focused therapy, and treat cannabis as a later option. Convenience made cannabis the easier product to reach for, but ease of access is not evidence of benefit. This is general information, not medical advice.